These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 23995712)

  • 1. The appraisal of public health interventions: an overview.
    Fischer AJ; Threlfall A; Meah S; Cookson R; Rutter H; Kelly MP
    J Public Health (Oxf); 2013 Dec; 35(4):488-94. PubMed ID: 23995712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The appraisal of public health interventions: the use of theory.
    Threlfall AG; Meah S; Fischer AJ; Cookson R; Rutter H; Kelly MP
    J Public Health (Oxf); 2015 Mar; 37(1):166-71. PubMed ID: 25015579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applicability and transferability of interventions in evidence-based public health.
    Wang S; Moss JR; Hiller JE
    Health Promot Int; 2006 Mar; 21(1):76-83. PubMed ID: 16249192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the role of economics in prioritization in public health: what do stakeholders think?
    Phillips CJ; Fordham R; Marsh K; Bertranou E; Davies S; Hale J; Kingsley M; Parke S; Porteous C; Rance J; Warm D
    Eur J Public Health; 2011 Oct; 21(5):578-84. PubMed ID: 20817687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pragmatism and realism for public health intervention evaluation].
    Ridde V; Haddad S
    Rev Epidemiol Sante Publique; 2013 Jun; 61 Suppl 2():S95-106. PubMed ID: 23684341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of public health interventions.
    Owen L; Morgan A; Fischer A; Ellis S; Hoy A; Kelly MP
    J Public Health (Oxf); 2012 Mar; 34(1):37-45. PubMed ID: 21933796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generalised cost-effectiveness analysis: an aid to decision making in health.
    Hutubessy RC; Baltussen RM; Torres-Edejer TT; Evans DB
    Appl Health Econ Health Policy; 2002; 1(2):89-95. PubMed ID: 14619255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The precautionary principle: advantages and risks].
    Tubiana M
    J Chir (Paris); 2001 Apr; 138(2):68-80. PubMed ID: 11319454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prioritizing investments in public health: a multi-criteria decision analysis.
    Marsh K; Dolan P; Kempster J; Lugon M
    J Public Health (Oxf); 2013 Sep; 35(3):460-6. PubMed ID: 23241415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of human parasitic diseases: Context and overview.
    Molyneux DH
    Adv Parasitol; 2006; 61():1-45. PubMed ID: 16735161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantifying benefit-risk preferences for medical interventions: an overview of a growing empirical literature.
    Brett Hauber A; Fairchild AO; Reed Johnson F
    Appl Health Econ Health Policy; 2013 Aug; 11(4):319-29. PubMed ID: 23637054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of economic evaluation in local health care decision-making in England: a qualitative investigation.
    Eddama O; Coast J
    Health Policy; 2009 Mar; 89(3):261-70. PubMed ID: 18657336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementing the Precautionary Principle: incorporating science, technology, fairness, and accountability in environmental, health, and safety decisions.
    Ashford NA
    Int J Occup Med Environ Health; 2004; 17(1):59-67. PubMed ID: 15212207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.